WiCON | Pharma China (Web Edition)

The Market

Industry News

Regulatory News

General Health

	Uncertainties Persist amid Conflicting Signals as China Intensifies Healthcare R...
	Chief Editor James Shen offers his monthly review of the Chinese healthcare sector with this issue's emphasis on latest market data analysis and mixed signs on the horizo... (8/1/2020)

WSJ: Drug Industry’s China Habit Will Take Time to Kick (8/7/2020)

Navigating The Latest Challenges Of China's Human Genetic Resources Regulation (8/6/2020)

China To Strengthen Regulation Of Human Genetic Resources (8/6/2020)

Review of Chinese Pharma Deals, R&D and Regulatory Developments in H1/2020 (8/5/2020)

Uncertainties Persist amid Conflicting Signals as China Intensifies Healthcare Reform and Cost Containment (8/1/2020)

China's Proposals to Provide a Patent Linkage System and Patent Term Extensions - Considerations for Drug Companies (7/29/2020)

China: Looking Back at 2019's Main IP Developments and Looking Forward At What 2020 May Bring (7/28/2020)

New Draft Patent Law - What To Expect and What Not to Expect (7/16/2020)

Long Awaited Chinese Civil Code - Impacts on IPR (7/14/2020)

China's Latest Patent Law Amendment Introduces Patent Linkage And Patent Term Extension (7/14/2020)

Revisiting the Basis of Your China Strategy in the Post-Covid New Normal (7/1/2020)

Trends in U.S. Multinational Enterprise Activity in China, 2000-2017 (7/1/2020)

Ex-USPTO Head, Retired Judge Back China Pharma IP Reform (6/30/2020)

How Data Protection Matters for Pharma Cos in Mainland China? - Ensuring Compliance and Mitigating Risk (6/30/2020)

In Depth: Decoding China's First Civil Code (6/23/2020)


	Innovent and Lilly Release Clinical Resu... (8/9/2020)
	NMPA Solicits Comments on the Draft Tech... (8/7/2020)
	Recent Executive Moves (8/7/2020)
	Lancet: Incidence of Multiple Sclerosis ... (8/7/2020)
	Pfizer/Basilea's NDA for Antifungal Isav... (8/7/2020)
	ImmVira and Shanghai Pharma Enter Deal f... (8/7/2020)
	Jacobio Pharma Aims to Raise $400M in Ho... (8/7/2020) (free)
	U.S. Introduces A 'Buy American First' P... (8/6/2020)
	AstraZeneca, Shenzhen Kangtai Enter Chin... (8/6/2020)
	Pfizer Fails to Secure Chinese Approval ... (8/6/2020)
	CDE Issues the Filing Requirements and P... (8/6/2020)
	NMPA Publicizes the List of Reference Fo... (8/6/2020)
	NMPA Solicits Comments on the Draft Inte... (8/6/2020)
	I-Mab Files IND for Eftansomatropin Pivo... (8/6/2020)
	Bayer's China Business Undermined by VBP... (8/6/2020)

	Pfizer to Absorb Mylan, Creating Global Generic Powerhou...
	PhRMA Calls for Trade Deals That Force Countries to Pay ...
	IQVIA: Global Pharma to Grow Slower in the Next Five Yea...
	Pfizer and GSK Announce JV to Create a Global Consumer H...
	Top 25 Global Pharmaceutical Companies by Market Cap 201...

	Nicholas Hall Reports 4.5% Growth for the Chinese OTC Analgesic...
	IQVIA: Overall Chinese Pharma Market Growth Rebounded to 8.4% i...
	China Oncology Drugs Market - Growth Opportunities Created by C...
	Snapshot of Chinese Non-prescription Drug Market 2016-2019
	IQVIA: Shanghai Drug Market Growth Up Substantially in 2019

	Pfizer/Basilea's NDA for Antifungal Isavuconazole (Cresemba)...
	ImmVira and Shanghai Pharma Enter Deal for Novel Intratumora...
	Jacobio Pharma Aims to Raise $400M in Hong Kong
	AstraZeneca, Shenzhen Kangtai Enter Chinese Vaccine Deal
	Pfizer Fails to Secure Chinese Approval for Its Zinforo NDA

	NMPA Solicits Comments on the Draft Technical Guidelines...
	CDE Issues the Filing Requirements and Procedures for Su...
	NMPA Publicizes the List of Reference Formulations for G...
	NMPA Solicits Comments on the Draft Interim Rules for Do...
	CDE Seeks Feedbacks on Draft Requirements for Applicatio...

	NPC Solicits Comments on 2nd Draft of the Chinese Patent Law...
	Punitive Damages in China's New Civil Code
	SAMR Issues Notice to Strengthen Anti-Unfair Competition Enf...
	Beijing Plans to Criminalize Criticisms of Traditional Chine...
	NPC to Prioritize Legislation on Public Health in 2020

	U.S. Introduces A 'Buy American First' Pharma Executive ...
	Fitch: No Near-Term Impact on Chinese API Makers as Phar...
	Indian Firms Challenged by API Price Hikes by Chinese Su...
	Snapshot of the Chinese API Sector
	India to Boost API Output as Alternative Source to China...

	Innovent and Lilly Release Clinical Results of TYVYT wit...
	I-Mab Files IND for Eftansomatropin Pivotal Trial in Ped...
	BioNTech, Fosun Start Clinical Trial of mRNA-based COVID...
	Legend Biotech: CDE Recommended Breakthrough Therapy Des...
	Terns Announces Completion and Positive Results from Pha...

	Lancet: Incidence of Multiple Sclerosis in China: A Nati...
	NHSA Solicits Feedbacks on the 2020 NRDL Revision Work P...
	NHSA Issues the Interim Measures for Administration of B...
	NHC Issues Notice to Step Up Single Disease Group Qualit...
	APO Issues Bidding Documents for the Third Batch of VBP

	Recent Executive Moves
	Recent Executive Moves
	Recent Executive Moves
	Recent Executive Moves
	Senior Chinese Pharma Official Investigated for Serious Le...

	USTR Satisfied with China's Implementatin of Phase 1 US-...
	U.S.-China ESRC Hearing: China's Evolving Healthcare Sys...
	AmCham Survey: Supply Chain Challenges for US Companies ...
	Upcoming Event: 2nd World Congress on Dermatology and Ae...
	Upcoming Event: XI International Exhibition of Equipment...

Pharma China is the most influential English media and source of business intelligence covering the Chinese pharmaceutical and biopharmaceutical sector...

WiCON has been helping international healthcare companies succeed in China and other Asian markets since 1991. We advise our clients on every stage of their China and Asian business. We worked with clients in many regions of the world...

WiCON Publishes the China Phar...

WiCON to Hold Pharma China Ann...

WiCON Publishes the China Phar...

WiCON Officially Publishes Chi...

Site map | Contact Us | Links